David E. Anderson
2021
In 2021, David E. Anderson earned a total compensation of $1.8M as Chief Scientific Officer at VBI Vaccines, a 49% increase compared to previous year.
Compensation breakdown
| Bonus | $185,000 |
|---|---|
| Option Awards | $1,205,000 |
| Salary | $410,000 |
| Other | $10,069 |
| Total | $1,810,069 |
Anderson received $1.2M in option awards, accounting for 67% of the total pay in 2021.
Anderson also received $185K in bonus, $410K in salary and $10.1K in other compensation.
Rankings
In 2021, David E. Anderson's compensation ranked 6,421st out of 12,406 executives tracked by ExecPay. In other words, Anderson earned more than 48.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,421 out of 12,406 | 48th |
Division Manufacturing | 2,744 out of 5,492 | 50th |
Major group Chemicals And Allied Products | 1,210 out of 2,368 | 49th |
Industry group Drugs | 1,078 out of 2,089 | 48th |
Industry Pharmaceutical Preparations | 780 out of 1,536 | 49th |
Source: SEC filing on April 29, 2022.
Anderson's colleagues
We found two more compensation records of executives who worked with David E. Anderson at VBI Vaccines in 2021.
News
VBI Vaccines CEO Jeffrey Baxter's 2023 pay falls 51% to $894K
April 29, 2024
VBI Vaccines CEO Jeffrey Baxter's 2022 pay falls 47% to $1.8M
May 1, 2023
VBI Vaccines CEO Jeffrey Baxter's 2021 pay jumps 54% to $3.5M
April 29, 2022
VBI Vaccines CEO Jeffrey Baxter's 2020 pay jumps 63% to $2.2M
April 26, 2021
VBI Vaccines CEO Jeffrey Baxter's 2019 pay slips 8% to $1.4M
April 28, 2020
VBI Vaccines CEO Jeffrey Baxter's 2018 pay jumps 81% to $1.5M
April 29, 2019